MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Indica Labs Unveils AI-Powered Macrodissection Suite to Enhance Molecular Pathology Workflows

NextEdge Admin

02 Aug 2024

2 min 59 sec

Indica Labs has introduced Lung Macrodissect AI, a transformative tool in digital pathology that enhances slide macrodissection and molecular pathology workflows. This AI-powered solution significantly improves the accuracy and efficiency of tumor content estimation and macrodissection, critical steps in molecular pathology. Traditional manual methods are often subjective, error-prone, and labor-intensive. In contrast, Lung Macrodissect AI quantifies tumor content across whole slide images, generating real-time data on tumor cell density to guide the annotation process.

Lung Macrodissect AI integrates with Indica Labs' HALO AP® platform and can pair with Xyall's Tissector robotic macrodissectors for a fully automated workflow. This integration enhances the accuracy and efficiency of the macrodissection process, allowing pathologists to focus on complex tasks. The tool also standardizes manual macrodissection workflows, ensuring only high-quality specimens are sent for genetic sequencing and molecular testing.

Clinical validation of Lung Macrodissect AI on 317 primary and metastatic slides showed significant improvements in consistency and agreement among pathologists. Without AI assistance, the inter-pathologist consistency (ICC) was 0.45 and agreement (Fleiss’ kappa) was 0.27. With AI assistance, the ICC increased to 0.75, and Fleiss’ kappa rose to 0.66, demonstrating substantial improvements.

Steven Hashagen, CEO of Indica Labs, highlighted the efficiency and accessibility advancements brought by Lung Macrodissect AI. Future launches include tools for colon, breast, and prostate macrodissection. Peter Caie, Senior Principal Scientist at Indica Labs, emphasized the tool's ability to objectively quantify tumor cells and streamline the annotation process.

Lung Macrodissect AI is available via the HALO AP® platform, known for its robust annotation, collaboration, and image analysis tools. HALO AP® supports various file types and complies with FDA, HIPAA, and GDPR regulations. While Lung Macrodissect AI is for research use only in the USA, HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland.